Damora Therapeutics, Inc. joined the Russell 2000 Growth Benchmark on June 29, 2026. The inclusion follows a period of increased market capitalization for the clinical-stage biotechnology firm.
The addition to the index typically drives demand from institutional investors and index-tracking funds. This shift often increases trading volume and share liquidity.
Damora recently reported positive developments, including new analyst initiations. The company also achieved significant progress across its therapeutic pipeline.